Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going
b'Host: Jennifer Caudle, DO
\\n\\n Guest: Sara A. Hurvitz, MD, FACP
\\n\\n Guest: Narjust Florez, MD
\\n\\n\\n \\n
This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non\\u2013small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates targeting HER3 will also be discussed.
'